Elite’s generic Adipex-P enters market
NORTHVALE, N.J. — Elite Pharmaceuticals has begun shipping an appetite suppressant for reducing weight in obese patients, the company said Thursday.
The drug maker announced the initial shipment of phentermine hydrochloride tablets in the 37.5-mg strength. The drug is a generic version of Teva’s Adipex-P.
Adipex-P and generic versions had sales of about $40 million in 2010, according to IMS Health.
The shipment was made under a collaborative agreement with precision dose and its subsidiary, TAGI Pharma.
Walgreens VP to present during Pinsonault Associates Managed Markets Summit
DEERFIELD, Ill. — Walgreens VP clinical affairs David Lorber will present during the Pinsonault Associates Managed Markets Summit on April 12 in Miami, Fla., the retailer announced Thursday.
The session, titled "Employer Issues in Specialty Pharmacy," will examine concerns for payers, including cost management and containment, benefit and coverage decisions, formulary and medical policy, pipeline management, provider network, member satisfaction and disruption, and compliance.
Specialty pharmacy is the most rapidly growing segment of total drug spending, Walgreens noted. Approximately 3% to 5% of the population is impacted, and that number is increasing. Lorber plans to discuss the goals of improving the health and well-being of patients by providing convenient access to drugs, consistent, coordinated support and maximum therapy outcomes, while also increasing adherence and eliminating direct costs resulting from medication waste. Walgreens specialty pharmacy offers patient assistance coordination, multiple distribution channels, strong manufacturer relationships, advanced clinical programs and access to limited distribution drugs.
Lorber joined Walgreens as the VP clinical affairs in November 2010 and is responsible for clinical oversight and consistency of Walgreens clinical programs. Previously, he was VP medical affairs for CVS Caremark. Prior to joining CVS Caremark, Lorber was medical director at Blue Cross Blue Shield of New Mexico in Albuquerque and a private practitioner in pulmonary, critical care and internal medicine. He has held numerous positions in community leadership and professional organizations, including president of the New Mexico Chapter of the American Thoracic Society and faculty appointments as assistant clinical professor of medicine with the University of New Mexico School of Medicine, and as assistant professor with the University of Arizona Medical Center in Tucson and the Tucson VA Hospital.
Pfizer, Zacharon enter collaboration
SAN DIEGO — Pfizer is partnering with San Diego biotech company Zacharon Pharmaceuticals to develop treatments for rare genetic disorders Zacharon said Thursday.
Under the collaboration, which could garner Zacharon up to $210 million, the companies will discover and develop pharmaceutical drugs for treating lysosomal storage disorders, a class of illnesses that includes Fabry disease, Gaucher disease, Pompe disease and Tay-Sachs disease.
Discovery of the drugs will involve use of Zacharon’s drug platform, and Zacharon will receive upfront payments, research and development funding and potential milestone payments and royalties.
“We are very pleased to be working with Pfizer, which has broad compound development expertise, including in the area of small molecules, which should be quite useful to developing drugs for these orphan diseases,” Zacharon president and CEO Robin Jackman said. “The collaboration provides validation for the potential that lies in Zacharon’s broadly applicable technology platform.”